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to platinum sensitivity, progression-free survival (PFS), over-
all survival (OS) and toxicity.  Results: Nine (11%) patients 
achieved a partial response and 34 (40%) stable disease, re-
sulting in a disease control rate of 51%. Response to treat-
ment was 49% in previously platinum-sensitive and 50% in 
previously platinum-resistant disease. The median PFS was 
3.1 months and the median OS 6.7 months. The most com-
mon grade 3 or 4 adverse events were mucositis (8%), pneu-
monia (8%), fatigue (8%) and skin reactions (14%). Sepsis oc-
curred in 3 patients.  Conclusion: Cetuximab plus docetaxel 
is an active treatment regimen with moderate toxicity in 
SCCHN patients. However, no superiority in comparison with 
monotherapy could be shown. Responsiveness and survival 
were independent of previous platinum sensitivity. 
 Copyright © 2013 S. Karger AG, Basel 
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 Abstract 
 Background: Cetuximab and docetaxel have single-agent 
activity in squamous cell carcinoma of the head and neck 
(SCCHN). The efficacy of their combination was evaluated in 
platinum-pretreated patients with recurrent and/or meta-
static SCCHN.  Patients and Methods: A total of 84 patients 
were treated with docetaxel 35 mg/m 2 weekly for a maxi-
mum of 6 cycles and concomitant cetuximab 250 mg/m 2 
weekly until disease progression or unacceptable toxicity. 
The primary endpoint was the objective response rate and 
secondary endpoints included the response rate in relation 
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 Introduction 
 Head and neck cancer is the 6th most common can-
cer in the world, with approximately 600,000 new cases
per year. Most head and neck cancers, approximately
90% in Western societies, are squamous cell carcinomas 
(SCCHN). For patients with recurrent and/or metastatic 
disease the prognosis is very poor. Patients experiencing 
disease progression on platinum-based chemotherapy 
have a bleak prognosis, with a reported median survival of 
just about 3 months  [1] . Patients with recurrent and/or 
metastatic disease without curative local treatment op-
tions are generally incurable, and currently available treat-
ment options for recurrent and/or metastatic disease are 
limited. The aims of treatment include palliation of symp-
toms and prevention from new cancer-related-symptoms, 
progression-free survival (PFS) and overall survival (OS).
 Chemotherapy is generally the treatment of choice in 
recurrent or metastatic disease. However, as results are 
very limited, there is a need for identification of new ther-
apeutic strategies in both patients without previous treat-
ment and in refractory patients. Recently, molecular-tar-
geted therapies are new treatment options for SCCHN. 
The most extensively studied molecular mechanism of 
action in SCCHN is the epidermal growth factor receptor 
(EGFR) pathway. The receptor is uniformly (90–100%) 
expressed in head and neck cancer cells. Cetuximab (Er-
bitux  ) is an IgG1 monoclonal antibody that induces an-
tibody-dependent cell-mediated cytotoxicity by inhibi-
tion of EGFR ligand binding  [2–7] . Cetuximab has dem-
onstrated single-agent activity in recurrent or metastatic 
SCCHN that progresses in spite of platinum-containing 
therapy. Chemotherapy has been combined with EGFR 
inhibitors as the two modalities differ in their mecha-
nisms of action  [8–12] . In recent years, taxanes have 
shown activity in SCCHN as single agent and as neoad-
juvant and concomitant chemotherapy combination reg-
imens. Weekly docetaxel at a dose of 30 mg/m 2 was active 
in a phase II study in chemotherapy-naive recurrent and 
metastatic SCCHN with a reported response rate of 42% 
and a median survival of 11.3 months  [13] . A phase II ran-
domized trial showed higher response rates for weekly 
docetaxel compared to methotrexate in pretreated pa-
tients (27 vs. 15%, respectively). However, the poor sur-
vival rates in both treatment arms warrant the search for 
more active regimens with acceptable toxicity  [14] . There-
fore, this study was designed to determine the efficacy 
and safety of the combination of weekly docetaxel plus 
cetuximab in platinum-pretreated patients with recur-
rent and/or metastatic SCCHN.
 Patients and Methods 
 Patient Selection 
 Patients were eligible if they were 18 years of age or older and 
had histologically or cytologically confirmed incurable recurrent 
and/or metastatic SCCHN. Other inclusion criteria included pri-
or platinum-containing chemotherapy; at least one lesion being 
measurable according to RECIST criteria 1.1, a Karnofsky perfor-
mance score (KPS)  6 70%, and adequate hematologic, renal and 
hepatic function. The main exclusion criteria were previous treat-
ment with docetaxel or previous exposure to an EGFR pathway-
targeting agent and symptomatic peripheral neuropathy.
 Study Design 
 This was an open-label, uncontrolled, interdisciplinary, mul-
ticenter, phase II study from the Arbeitsgemeinschaft Internist-
ische Onkologie (AIO), which was conducted at 10 institutions in 
Germany. The primary endpoint was the objective response rate 
according to RECIST criteria. Secondary endpoints were re-
sponse rate in relation to previous platinum sensitivity or plati-
num resistance, PFS (time from first dose of medication to the 
first confirmation of disease progression or the day of death as a 
result of any cause within 60 days after the last tumor assessment), 
OS (time from the first dose of medication to death) and safety. 
Adverse events were graded according to Common Toxicity Cri-
teria (version 3.0). Platinum resistance was defined as disease pro-
gression within 3 months following the last platinum administra-
tion. The study was designed by the Head and Neck Committee 
of the AIO. Data were collected by the investigators at each center. 
The trial protocol and amendment were approved by the indepen-
dent ethics committee of each center and by the authorities in 
Germany. The trial was conducted in accordance with the Decla-
ration of Helsinki (1996). All patients provided written informed 
consent.
 As an optional side study, blood and tissue samples were col-
lected in patients who consented to blood collection in order to 
investigate potential prognostic factors. These investigations have 
been published elsewhere  [15, 16] .
 Treatment 
 Patients received cetuximab at an initial dose of 400 mg/m 2 
body surface area given as a 2-hour intravenous infusion, fol-
lowed by subsequent weekly doses of 250 mg/m 2 as 1-hour intra-
venous infusions, ending at least 1 h before the start of chemo-
therapy. Docetaxel at a dose of 35 mg/m 2 as a 1-hour intravenous 
infusion was administered on days 1, 8 and 15 every 4 weeks. Dose 
modifications of cetuximab and docetaxel were permitted ac-
cording to protocol-specified criteria. Patients received a maxi-
mum of 6 cycles (18 doses) of docetaxel in the absence of limiting 
toxicity or disease progression. After a maximum of 6 cycles of 
chemotherapy, patients who continued to have at least stable dis-
ease received further cetuximab maintenance treatment until dis-
ease progression or unacceptable toxicity.
 Assessment 
 Tumor evaluation was assessed by computed tomography or 
magnetic resonance imaging at baseline and at 8-week intervals 
until disease progression. The RECIST criteria were used to de-
termine tumor response and disease progression. Blood samples 
(blood cell count, serum chemistry and electrolytes) were taken 
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on a regularly basis for evaluations of toxicity. Concomitant med-
ications and adverse events were monitored weekly throughout 
the study. Survival status and any further anticancer treatments 
were documented at follow-up visits every 3 months after disease 
progression. 
 Statistical Analysis 
 Continuous variables were summarized using descriptive sta-
tistics. Categorical variables were summarized using counts and 
percentages. Two-sided confidence intervals (CI) according to 
Clopper-Pearson were calculated for response rates. Kaplan-Mei-
er estimates were used for time to event parameters, including PFS 
and OS. The response rates according to platinum sensitivity ver-
sus platinum resistance were compared using Fisher’s exact test. 
Cox’s proportional hazard model was used for multivariate anal-
ysis to identify independent prognostic factors for survival. The 
primary population for efficacy analyses was the intent-to-treat 
population (defined as all patients enrolled into the study). Safety 
analyses were conducted on the safety analysis set, defined as all 
patients enrolled into the study who received at least one dose of 
cetuximab and docetaxel. The trial initially had a two-stage de-
sign: if  ^  1 response was observed in the first 18 patients, the study 
had to be stopped due to futility. Otherwise accrual was to be con-
tinued to a total of 47 patients, and if the total number of respons-
es were to exceed 4, cetuximab in combination with docetaxel 
should be further investigated. For more robust determination of 
the secondary endpoint PFS, an amendment to the protocol was 
instituted to increase the accrual to 84 patients and provide an 
estimate of PFS suitable for planning future randomized trials.
 Results 
 A total of 84 patients were enrolled at 10 institutions 
in Germany within 17 months between December 2006 
and April 2008. All patients were included in the intent-
to-treat population. The safety population comprised 84 
patients. Nine patients who received 6 cycles of chemo-
therapy continued treatment with cetuximab mainte-
nance.
 Patient Characteristics 
 Demographic and clinical baseline characteristics are 
listed in  table  1 . The patient population comprised 69 
males with a median age of 59 years. Baseline KPS was 
good (KPS 90–100%) in 19% of the patients. The most 
common site of the primary tumor was the oropharynx 
(33%;  table 1 ). Distant metastases were present in 39% of 
patients. The median number of previous treatments in-
cluding operation, radiotherapy and chemotherapy was 2 
(range, 1–9). The disease was regarded as platinum sensi-
tive in 56% of the patients, platinum resistant in 26% of 
the patients and not evaluable in further 18% of the pa-
tients due to lack of data.
 Exposure to Treatment 
 The median duration of treatment was 2.9 months 
(range, 0–17.7). Patients received a median number of 3.3 
cycles with docetaxel and a median number of 3.7 cycles 
with cetuximab. Nine patients (11%) received cetuximab 
monotherapy as the maintenance treatment, with a me-
dian duration of 11.6 months.
 Treatment Efficacy 
 According to the RECIST criteria, the overall response 
and disease control rate (DCR) included 9 partial respons-
es and 34 patients with stable disease, respectively, result-
ing in an overall response rate of 11% and a DCR of 51% 
( table 2 ). No patient achieved a complete response. There 
were, additionally, 3 short-lived responses after 2 cycles 
that were not confirmed, because of progression after 4 
cycles. The overall median duration of response was 126 
days. Protocol subgroup analyses showed that the overall 
responses to the study treatment of platinum-sensitive and 
-resistant patients were very similar in both subgroups: 11 
of the 22 platinum-resistant patients experienced disease 
control (DCR 50%) and 23 of the 47 platinum-sensitive pa-
Table 1. D emographic and clinical characteristics of the patients 
at baseline
Characteristics Patients, n (%)
Total cohort 84
Males 69 (82)
KPS
90–100% 16 (19)
70–80% 63 (75)
Not evaluable 5 (6)
Primary tumor site
Hypopharynx 12 (14)
Larynx 4 (5)
Oropharynx 28 (33)
Oral cavity 16 (19)
Other 14 (17)
Not evaluable 10 (12)
Extent of disease at inclusion
Metastatic 33 (39)
Recurrent 18 (21)
Recurrent and metastatic 17 (20)
Not evaluable 16 (20)
Response to platinum-based therapy
Platinum sensitive 47 (56)
Platinum resistant 22 (26)
N ot evaluable 15 (18)
Me dian age of the patients was 59 years (range, 34–79).
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tients (DCR 49%). Previous platinum sensitivity was not 
predictive for PFS (p = 0.4) and OS (p = 0.94).
 Time to Progression, PFS and OS 
 The median PFS was 3.1 months (95% CI, 2.3–3.9; 
 fig. 1 ) and the proportion of patients without progression 
was 21% at 6 months and 7% at 1 year. The median OS 
was 6.7 months (95% CI, 5.3–8.0;  fig. 1 ) with 58% of pa-
tients alive at 6 months and 25% at 1 year. Among the 
patients receiving cetuximab maintenance after comple-
tion of the combination period, the median further PFS 
was 18 weeks from the start of maintenance treatment.
Table 2. R esponse to treatment
Response variable Patients, n (%)
Best response
Partial response 9 (11)
Stable disease 34 (40)
Progressive disease 36 (43)
Not evaluable 5 (6)
DCR 43 (51)
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 Fig. 1. Kaplan-Meier estimates of survival. 
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 Multivariate analysis did not reveal a prognostic factor 
for survival, considering the following variables: plati-
num sensitivity, age, sex, extent of disease (locally recur-
rent/metastatic), primary tumor site, and exposure to to-
bacco or alcohol.
 Safety 
 The safety profile was consistent with the anticipated 
toxicity for both agents used. The most common hema-
tologic adverse event of grade 3 and 4 was anemia in 5% 
of the patients. The most frequent non-hematologic ad-
verse events were skin reactions, mucositis, pneumonia 
and fatigue. Skin reactions included rash, acne, nail dis-
orders and dry skin. Two patients had severe infusion-
related reactions. Sepsis occurred in 3 patients and febrile 
neutropenia in 2 patients. Adverse events of grade 3 and 
4 were observed in 67% of the patients ( table 3 ). Serious 
adverse events, mostly grade 3 or 4, were reported in 46 
patients (55%). Four patients died during the chemother-
apy phase for reasons not related to tumor progression. 
Causes of death in these 4 patients included sudden death, 
catheter port infection and subsequent pneumonia, PEG 
tube infection and subsequent pneumonia during neu-
tropenia, and sepsis from superinfected tumor.
 Discussion 
 Locoregional or distant relapses occur in approxi-
mately half of the SCCHN patients, and treatment re-
mains unsatisfactory in patients with relapse after plati-
num-containing treatment. At present, no standard regi-
men is available in this setting. Several phase II trials have 
examined numerous systemic treatment options mostly 
in first-line treatment with several cytotoxic agents, in-
cluding docetaxel and also cetuximab monotherapy, with 
overall response rates between 10 and 20% and a median 
survival of 6–9 months  [10–13] . Here we report clinical 
activity of the combination of docetaxel with cetuximab 
in second-line systemic treatment. Given the unfavorable 
patient characteristics of our cohort, our results compare 
well with other treatment regimens investigated in this 
disease. The results of this study compare well to those 
for single-agent docetaxel in recurrent and/or metastatic 
SCCHN with overall response rates between 6.7 and 13%, 
with a corresponding DCR of 33–34% in several studies. 
However, in several studies, response rates were higher 
than in our study, irrespective of whether a weekly or a 
3-weekly regimen was used  [13, 14, 17] . Median PFS and 
OS of 7.4–9 and 17.9–29 weeks, respectively, have been 
reported previously  [14, 17, 18] . The survival data were 
remarkably similar to OS and PFS in our study. These dif-
ferences could be potentially explained by differences in 
the study population as most of these studies included 
chemonaive patients or patients with a treatment-free in-
terval of more than 6 or 12 months since the end of their 
initial treatment, or who had not received prior chemo-
therapy for recurrent and/or metastatic disease. Similar 
response rates with an overall response rate of 13% and 
about 6 months of OS were reported by cetuximab mono-
therapy  [8] . Compared to the combination of cetuximab 
plus docetaxel, cetuximab as single agent has a mild tox-
icity profile. In both settings, docetaxel monotherapy or 
in combination with cetuximab, moderate toxicities were 
seen. The adverse events observed in our study were those 
expected with the agents used. Mucositis is commonly 
observed with docetaxel. Grade 3/4 toxicities were re-
ported in 8% of the patients. Grade 3/4 pneumonia was 
also observed in 8% of the patients, a percentage not re-
ported in other trials. The discrepancy may be due to dif-
ferences in patient selection. It is worth noting that in our 
study only pretreated and mostly preradiated patients 
were included. All patients have been heavy smokers with 
pulmonary comorbidities. In contrast to observations 
with cetuximab therapy, the incidence of grade 3/4 skin 
toxicities (14%) is low. No discrepancy in hematological 
toxicities was seen compared to docetaxel monotherapy.
 One of the most unfavorable factors in many cancers 
is resistance to platinum treatment. In several other can-
cer types, namely ovarian cancer, platinum-refractory 
disease has been defined as progression within 6 months 
Table 3. G rade 3/4 adverse events
Adverse events n %
Skin reactions 12 14
Mucositis 7 8
Pneumonia 7 8
Fatigue 7 8
Anemia 4 5
Sepsis 3 4
Tumor hemorrhage 3 4
Decreased performance status 3 4
Dyspnea 3 4
Headache 2 2
Febrile neutropenia 2 2
Infusion-related reactions 2 2
Cardiac events 1 1
Perforation of a duodenal ulcer 1 1
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after completion of platinum-containing chemotherapy. 
A similar definition has not been employed for SCCHN; 
however, most clinical trials have excluded patients with 
progression within an interval of at least 6 months after 
prior cisplatin exposure, whereas 27% of our patients en-
tered the study after progression on or briefly after prior 
cisplatin treatment. Unexpectedly, the efficacy of our 
study treatment appeared to be independent of prior plat-
inum sensitivity, which suggests that there is no relevant 
cross-resistance of the two approaches. The consequence 
of the latter observation is twofold: on the one hand, the 
combination of docetaxel and cetuximab is an active 
treatment option for patients with recurrent and/or met-
astatic SCCHN regardless of prior treatment, but on the 
other hand, the three agents cisplatin, docetaxel and ce-
tuximab appear to be potential candidates for combina-
tion first-line treatment or induction therapy based on 
the apparent lack of overt cross-resistance. This is cur-
rently being investigated in a first-line, randomized, 
phase II trial conducted by the AIO Head and Neck Can-
cer Group.
 In conclusion, the results of our study are in line with 
single-agent docetaxel and with those of cetuximab 
monotherapy in more selected patient populations with 
metastatic and/or recurrent disease and warrant further 
investigation in randomized trials.
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